Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

Epifadin from the nasal microbiome - 28/03/2024

From the nose: novel antibiotic substance discovered

Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.

Vaccine development - 02/06/2020

CureVac as a pioneer of mRNA technology - what is behind the novel COVID-19 vaccine?

All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.

Article - 30/09/2019

Do gut bacteria have something to do with autism?

Autistic people have different gut microorganisms than non-autistic people. Researchers believe that a disturbed intestinal flora may play a role in developmental disorders of the brain such as autism. The emerging new field of metaproteomics could shed light onto the matter. A team led by Prof. Dr. Boris Macek from Tübingen has investigated the bacterial protein pool in the faeces of mice that display autistic behaviour.

A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.

Neurodegenerative diseases - 12/12/2022

Blood-based biomarkers allow the early prediction of Alzheimer's risks

Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates.

In the 2022 allocation round for the award of the prestigious Consolidator Grants of the European Research Council, researchers of Karlsruhe Institute of Technology (KIT) have been successful. For their projects in the fields of photovoltaics and medical sensor technology, physicist Ulrich W. Paetzold and chemist Frank Biedermann will receive approximately two million euros over the next five years.

Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.

Konstanz chemists develop mineral plastics with numerous positive properties from sustainable basic building blocks and, together with biologists, demonstrate the material's excellent microbiological degradability.

If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene activity using methyl groups is responsible.

Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand donors.

The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.

Dossier - 28/08/2018

With molecular diagnostics to biomarker-based personalised therapy

Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

Article - 29/01/2019

Targeted RNA editing with the body’s own enzyme activity

Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…

Whether we are predisposed to particular diseases depends to a large extent on the countless variants in our genome. However in the case of genetic variants the influence on the presentation of certain pathological traits has been difficult to determine. Researchers have introduced an algorithm based on deep learning that can predict the effects of rare genetic variants.

They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role in the development of this disease.

Dossier - 12/03/2012

Regenerative medicine makes use of patients own resources

Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.

EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.